Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
Screened 2026-09-11 · the tape above runs as of 15:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Novanta Inc. holds its Distribution at $146.56. Consolidating, no directional conviction, held for 11 days.
As held on the ledger · 2026-09-11
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 11 days
Price at the screen
$146.56
Valuation
92.76 trailing · 33.56 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.68
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
16.71%
Below 33%
Interest-bearing debt is just 16.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
31.31%
Below 49%
Money owed to the company is 31.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 5.1% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus Strong Buy. The average target sits +33% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Precision Parts Maker Priced Well Beyond Its Worth
Picture a surgeon relying on exact laser cuts during an operation or a factory robot slotting parts with zero tolerance for error. Novanta supplies those niche components across medical and automation markets. Yet at 35.9 times forward earnings, with revenue growing just 10 percent, margins stuck at 5 percent and return on equity also at 5 percent, the shares sit 5 percent above our fair value and carry no opportunity rating.
The business clears our ethical screen, which rules out many peers in the sector. That is the only clear positive. Everything else points to a company whose returns fail to justify the multiple investors are paying, especially when the moat remains unclear and only two analysts even bother to publish targets.
Valuation leaves little room for execution slips or slower adoption of its tools. Currency swings and customer concentration in medical equipment add further pressure that thin margins cannot easily absorb. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NOVT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-06Distribution$139.65-14.5%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 14.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (2 analysts) rates it none, with a mean price target of $172.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 1.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (2 analysts) rates it none, with a mean price target of $172.
2026-07-18Markup$160.53+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 19%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (2 analysts) rates it none, with a mean price target of $172.
2026-07-03Markup$160.53+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$160.53Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
